Table 2

Patients characteristics by treatment arm and EGFR status determined on cfDNA (n=354)

EOX armEOX-P arm
EGFR non-amplified (<2)EGFR amplified (≥2)EGFR non-amplified (<2)EGFR amplified (≥2)
Median age (IQR)62.8 (56.1–68.3)60.8 (49.8–65.3)63.4 (55.8–69.9)62.7 (50.2–67.1)
Males (%)139 (85.3)3 (75)138 (81.7)16 (88.9)
Females (%)24 (14.7)1 (25)31 (18.3)2 (11.1)
PS 0 (%)70 (42.9)2 (50)77 (45.6)10 (55.5)
PS 1 (%)82 (50.3)2 (50)85 (50.30)7 (38.9)
PS 2 (%)11 (6.8)   –7 (4.1)1 (5.6)
Locally advanced (%)20 (12.3)  –26 (15.4)2 (11.1)
Metastatic (%)143 (87.7)4 (100)143 (84.6)16 (88.9)
  • cfDNA, cell-free DNA; EGFR, epidermal growth factor receptor; EOX, epirubicin, oxaliplatin, capecitabine; P, panitumumab; PS, performance status.